<DOC>
	<DOCNO>NCT00796276</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics paliperidone plasma urine intravenous ( i.v . ) administration racemate , administration immediate-release ( IR ) racemate oral solution , administration ER OROS tablet , administration oral solution individual enantiomer R078543 ( + ) R078544 ( - ) ; determine absolute oral bioavailability IR ER OROS paliperidone ; document ( + ) ( - ) paliperidone enantiomer ratio i.v . oral administration ( IR ER OROS paliperidone ) ; document possible interconversion ( + ) ( - ) enantiomers paliperidone oral treatment separate enantiomer ; document possible relationship subject 's CYP2D6 phenotype ( + ) ( - ) enantiomer disposition paliperidone ( CYP2D6 genotyping use corroborate phenotype ) . In addition , safety tolerability treatment evaluate .</brief_summary>
	<brief_title>A Study Paliperidone Enantiomer Disposition With Different Formulations Bioavailability Immediate- Extended-release Paliperidone</brief_title>
	<detailed_description>This single-center , single-dose , open-label , randomize , crossover study healthy adult , follow 5-sequence , 5-treatment , 5-period Latin square design . The study consist screen phase ( within 21 day first administration study drug ) , treatment phase consist 5 period volunteer receive single dose study drug fast condition [ orally 240 mL water intravenously ( i.v . ) ] random order . Pharmacokinetic blood urine sample collect 96-hour period follow study drug administration treatment period . Volunteers confine test facility least 10 hour dose 72 hour dose treatment period return additional assessment . Each administration study drug separate washout period least 7 maximum 14 day . The duration volunteer participation maximally 12 week , include 3 week screening period . CYP2D6 metabolizer status assess phenotyping corroborate genotyping DNA sample collect volunteer consent part study . Pharmacokinetic data available oral administration immediate release extend release formulation paliperidone . No data available i.v . administration paliperidone . The data obtain study i.v . route important characterize pharmacokinetics paliperidone , future population pharmacokinetics model paliperidone . For chiral substance , request regulatory authority guideline document disposition enantiomer . Therefore , disposition ( + ) ( - ) enantiomers paliperidone different administration route ( i.v . oral ) formulation ( immediate release extend release [ ER OROS ] ) document . Separate enantiomer administer study , important full understanding pharmacokinetics paliperidone document possible chiral interconversion . Safety tolerability monitor throughout study . 5 single dos , one : Treatment A , 1 mg IR paliperidone oral solution ; Treatment B , 3 mg ER OROS paliperidone oral ; Treatment C , 1 mg paliperidone 30-min i.v . infusion ; Treatment D , 1 mg ( + ) -paliperidone ( R078543 ) oral solution ; Treatment E , 1 mg ( - ) -paliperidone ( R078544 ) oral solution .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Known dextromethorphan ( i.e. , previously determine ) metabolic ratio &lt; 0.02 &gt; 0.35 , determine accord standard procedure study center Acceptable weight define body mass index ( weight [ kg ] /height [ m² ] ) range 18 28 kg/m² , inclusive Normotensive supine ( 5 minute ) blood pressure range 100 140 mmHg systolic , inclusive , 60 90 mmHg diastolic , inclusive Nonsmoking habitually smoke 10 cigarette , 2 cigar , 2 pipe tobacco per day least 6 month prior study enrollment Healthy basis prestudy screen physical examination , medical history , ECG , laboratory result blood biochemistry , hematology , urinalysis perform within 21 day first study drug dose . If result biochemistry , hematology , urinalysis test within reference laboratory range , volunteer include investigator judge deviation clinically significant . For renal function test , value must within normal laboratory reference range Women must practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , double barrier method , contraceptive transdermal patch , male partner sterilization , discretion investigator , total abstinence ) , postmenopausal least 1 year , surgically sterile entry throughout study Women volunteer must also negative serum pregnancy test screening . Known allergy history significant hypersensitivity heparin , case heparin lock use Drug allergy risperidone , paliperidone , excipients Recent history alcohol substance abuse and/or test positive urine drug screen study screen Relevant history cardiovascular , respiratory , neuropsychiatric , renal , hepatic , gastrointestinal ( include surgery , malabsorption problem , history severe preexist gastrointestinal narrowing [ pathologic iatrogenic ] ) , endocrine , immunologic disease , significant finding physical examination History cancer , exception basal cell carcinoma At screening , sustain drop systolic ( &gt; 20 mmHg ) diastolic ( &gt; 10 mmHg ) blood pressure stand least 2 minute associated increase pulse rate &gt; 15 beat per minute Positive result serology test ( hepatitis BsAg , CAb , HIV1 ) Consuming 450 mg caffeine per day . This equal 5 cup tea , 3 cup coffee , 8 can cola</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Mood disorder</keyword>
	<keyword>Antipsychotics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Enantiomer</keyword>
	<keyword>IR OROS Paliperidone</keyword>
	<keyword>ER OROS Paliperidone</keyword>
</DOC>